Big Molecule Watch
- Year in Review: Top Legal Developments of 2024 January 14, 2025 Timothy Beavers|Kevin DeJong|Alexandra Lu|Joshua Weinger
- The 43rd Annual J.P. Morgan Healthcare Conference Starts Today – A Who’s Who in Biologics at this Year’s Conference January 13, 2025 Beth Ashbridge
- Year in Review: Top Regulatory Developments of 2024 January 10, 2025 Timothy Beavers|Seth Manilove
- Acuitas Sues GSK Seeking Declaratory Judgment of Invalidity and Non-Infringement of mRNA Vaccine Patents January 10, 2025 Riley Wyberg
- Recent Ustekinumab and Denosumab Biosimilars Deals January 7, 2025 Yoko Bian
- FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba) January 6, 2025 Daniel Farraye
- Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation? December 31, 2024 Huiya Wu|Michael Siekman
- EMA’s CHMP Recommends Approval of Six New Biosimilars December 26, 2024 Sam Herron
- Bio-Thera Solutions Expands Partnership with SteinCares to Market Two Biosimilars in LATAM December 19, 2024 Alison Siedor
- FDA Approves New Biologic Cancer Treatments December 16, 2024 Emma Murray
BioPharma Reporter
- Hinge Bio raises $30 million to progress B cell lupus therapy January 16, 2025
- Umoja raises $100 million to boost its CAR-T cell gene therapy pipeline January 16, 2025
- Regenxbio and Nippon Shinyaku collaborate to develop and commercialize gene therapies for Mucopolysaccharidosis I and II January 14, 2025
- Windward Bio launches to develop potential best-in-class antibody against asthma and COPD January 14, 2025
- MaaT Pharma’s microbiome therapy scores phase 3 win January 9, 2025
- Alchemab and Lilly collaborate to discover and develop ALS therapies January 9, 2025
- BrainChild Bio advances development of CAR T therapy for pediatric brain tumors January 7, 2025
- Adcentrx launches Phase 1 study for its next-generation ADC targeting advanced solid tumors January 7, 2025 Rachel Arthur
- Orbis Medicines bags €90 million Series A to develop oral competitors of biologics January 6, 2025 Jonathan Smith
- Roche and Prothena’s Parkinson’s antibody treatment fails at phase 2 December 19, 2024